Engineered Bacteria Target Colorectal Cancer Organoids
Researchers report that two engineered bacterial strains preferentially colonize patient-derived colorectal cancer organoids over matched normal tissue.
Updated on Nov. 18, 2026 in Life Sciences

Both engineered bacterial strains preferentially colonized colorectal cancer organoids over matched normal mucosa in a co-culture study. Attenuated Salmonella typhimurium achieved higher colonization efficiency and a greater impact on host responses than Escherichia coli Nissle 1917.
Why it matters
The findings support attenuated Salmonella as a particularly effective chassis for future engineered bacterial therapies targeting colorectal cancer. Responses were strain-dependent and patient genotype-dependent, indicating that treatment effects may vary between individuals.
The study compared two engineered bacterial strains across two genotypically distinct patient-derived organoid lines, using colony-forming unit assays and time-lapse fluorescence imaging to quantify colonization. Whether these laboratory results predict outcomes in human patients has not been established.
The players
GenCirq Inc.
GenCirq Inc. is a biotechnology company disclosed as holding a competing interest in the research, which is reported as a declared financial relationship rather than an allegation.
The details
Researchers paired patient-derived colorectal cancer and matched normal mucosa organoids with two engineered bacterial strains in a co-culture platform. Host responses were characterized through transcriptomic profiling, histological staining, quantitative morphological analysis, and secondary organoid-forming assays.
The Big Picture
The study extends the line of research using engineered bacteria as cancer-targeting delivery vehicles, comparing attenuated Salmonella against the probiotic strain Escherichia coli Nissle 1917 in patient-derived tissue models. Its strain-dependent results suggest the choice of bacterial chassis matters for therapies that rely on selective tumor colonization.
For patients, this research is early-stage and does not yet change available treatment options for colorectal cancer. The results indicate that any future bacterial therapy would likely need to be tailored to tumor genotype and to the specific bacterial strain used.
The takeaway
Engineered bacteria show promise as tumor-targeting tools, but their effects vary by bacterial strain and patient genotype. Results from laboratory organoid models must be confirmed in living systems before any clinical use.
Further reading
Explore more research on Life Sciences to see how engineered organisms are being studied in medicine.
Source note: This article includes information reported by Nature.



